Statistics for Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT
Total visits
| views | |
|---|---|
| Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT | 0 |
Total visits per month
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
File Visits
| views | |
|---|---|
| java.util.UUID:a27c065c-901a-43fa-ab86-54354f9555ae | 5 |
| Tarantino2024Adjuvant-CCBYNCND.pdf | 3 |
| java.util.UUID:c04f0319-98ae-4f31-a06a-ed5193c065f7 | 3 |
| java.util.UUID:f2ffc83e-3c5b-43d6-8174-8b73c899d31a | 1 |